After a heart attack, levels of blood lipids such as low-density lipoprotein cholesterol (LDL-C) may influence the risk of further cardiovascular events. In this analysis, we determined that even when LDL-C levels are controlled with a statin, elevated levels of another blood lipid called lipoprotein(a) are associated with an increased risk of further cardiovascular events and a benefit of treatment with the PCSK9 inhibitors.

In this interview, Gregory G. Schwartz, MD, PhD and Glenn A. Hirsch MD, MHS, FACC, with Lindsay Panah, MD, discuss Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients with Nominally Controlled LDL-Cholesterol.

Is atrial fibrillation ablation a "slam dunk" for athletes? When would a clinician favor pharmacotherapy?

In this episode, Michael S. Emery, MD, MS, FACC debates Mark S Link, MD on Atrial Fibrillation Management in Athletes, moderated by Alison L. Bailey, MD FACC.

Studies have demonstrated dysfunction of the left atrium and right atrium were linked to lower ability to walk, and may be a precursor to heart failure. It may be useful to examine the function of the atria on echocardiography to understand one's risk of developing heart failure in the future.

In this interview, Ravi B. Patel, MD, MSc and Roger S. Blumenthal MD, FACC, with Aaysha Cader, MBBS, MD, MRCP, discuss Associations of Cardiac Mechanics with Exercise Capacity: The Multi-Ethnic Study of Atherosclerosis.

Use of the newer high-sensitivity troponins offer significant advantages, but with a number of caveats.  Although the ability to accelerate the exclusion of myocardial infarction in many patients within just a few hours of ED presentation, the increased sensitivity can potentially lead to diagnostic confusion as more patients will have detectable troponin indicating myocardial injury not associated myocardial infarction.

In this interview, Michael C Kontos, MD, FACC, Ana Barac MD, PhD, FACC, with Aaysha Cader, MBBS, MD, MRCP, discuss High-Sensitivity Troponin in The ED: Pearls And Pitfalls of Wide-spread Utilization.

Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL

Syncope occurs commonly in the general population and apart from risks of injury due to physical collapse, they can cause patients considerable anxiety and diminished quality-of-life. Better understanding of the syncope 'landscape' can help practitioners provide more effective prevention strategies while permitting patients to cope more effectively with fears of recurrences.

In this interview, David G Benditt, MD, FACC, FHRS, FESC, FRCPC, CCDS and Thomas F. Deering MD, FACC discuss The Serious (and Not So Serious) Side of Faints and Falls: Is My Syncope Patient at Increased Risk?

Related References: 

1. ACC/AHA/HRS Versus ESC Guidelines for the Diagnosis and Management of Syncope: JACC Guideline Comparison. J Am Coll Cardiol 2019;74:2410–2423. 

1. Benditt DG, van Dijk JG, Krishnappa D, Adkisson WO, Sakaguchi S. Neurohormones in the Pathophysiology of Vasovagal Syncope in Adults. Front Cardiovasc Med 2020;7:76. 

Explore the timing of aortic valve replacement, the choice between TAVI vs. SAVR, and special considerations in the management of aortic stenosis. In this interview, Catherine Otto, MD, FACC and Uma Narasimhan Srivatsa MBBS, FACC, with Matt A. Cavender MD, MPH, FACC, discuss Putting it All Together: Guidelines in the Management of Aortic Stenosis.

In this interview, Dhanunjaya "DJ" Lakkireddy, MBBS, FACC, Andrew Kates, MD, FACC and Alison L. Bailey, MD FACC, discuss their top takeaways from 2021 in electrophysiology and general Cardiology.

In this interview, Christopher M. Kramer, MD, FACC, Deepak L. Bhatt, MD, and Alison L. Bailey, MD FACC discuss their top takeaways from 2021 in cardiovascular imaging and interventional cardiology. Join these ACCEL Leaders as they walk through the most impactful advances of the year.

Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL

In this interview, Clyde W. Yancy, MD, FACC, C. Noel Bairey Merz, MD, FACC and Alison L. Bailey, MD, FACC discuss their top takeaways from 2021 in heart failure and preventive cardiology. These ACCEL Leaders discuss new data regarding SGLT2is, the association of SGLT2i and quality of life measured by KCCQ strata and done so in an entirely virtual space. These are major new data points and infer intriguing new ways to generate original data. What is the message for implementation and cost? Dive into new aspirin data and guidance, COVID myocarditis, and the STEP and ORION trials in this episode.

Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL

Failure to initiate an SGLT2i to an eligible HFrEF patient exposes the patient to higher risk of early post-discharge death and readmission, and the real risk that the medication never gets prescribed at all.

In this interview, Stephen J. Greene, MD and Christopher B. Granger MD, FACC, with Ioannis Mastoris, MD, MPH, discuss In-Hospital Initiation of Sodium Glucose Cotransporter-2 Inhibitors for Heart Failure with Reduced Ejection Fraction.

Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL